Literature DB >> 9512308

Intravenous immunoglobulin treatment of children with autism.

A V Plioplys1.   

Abstract

Since autism has been associated with immunologic abnormalities suggesting an autoimmune cause of autistic symptoms in a subset of patients, this study was undertaken to investigate whether intravenous immunoglobulin (i.v.Ig) would improve autistic symptoms. Ten autistic children with immunologic abnormalities, demonstrated on blood tests, were enrolled in this study. Their ages ranged from 4 to 17 years, with two girls and eight boys. Eight children (1 female and 7 male) historically had undergone autistic regression. Intravenous immunoglobulin, 200 to 400 mg/kg, was administered every 6 weeks for an intended treatment program of four infusions. In five children, there was no detectable change in behavior during the treatment program. In four children, there was a mild improvement noted in attention span and hyperactivity. In none of these children did the parents feel that the improvement was sufficient to warrant further continuation of the infusions beyond the termination of the program. Only in one child was there a very significant improvement, with almost total amelioration of autistic symptoms over the time period of the four infusions. Once the treatment program was completed, this child gradually deteriorated over a 5-month time period and fully reverted to his previous autistic state. In this treatment program, five children had no response to intravenous immunoglobulin. In the four children who showed mild improvements, those improvements may simply have been due to nonspecific effects of physician intervention and parental expectation (ie, placebo effect). However, in one child there was a very significant amelioration of autistic symptoms. There were no distinguishing historic or laboratory features in this child who improved. Given a positive response rate of only 10% in this study, along with the high economic costs of the immunologic evaluations and the intravenous immunoglobulin treatments, the use of intravenous immunoglobulin to treat autistic children should be undertaken only with great caution, and only under formal research protocols.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9512308     DOI: 10.1177/088307389801300207

Source DB:  PubMed          Journal:  J Child Neurol        ISSN: 0883-0738            Impact factor:   1.987


  25 in total

1.  Regarding secretin for treating autistic disorder.

Authors:  M G Aman; S A Armstrong
Journal:  J Autism Dev Disord       Date:  2000-02

2.  Immunological treatments for autism.

Authors:  S Gupta
Journal:  J Autism Dev Disord       Date:  2000-10

Review 3.  Immune dysfunction in autism: a pathway to treatment.

Authors:  Milo Careaga; Judy Van de Water; Paul Ashwood
Journal:  Neurotherapeutics       Date:  2010-07       Impact factor: 7.620

Review 4.  Immune therapy in autism: historical experience and future directions with immunomodulatory therapy.

Authors:  Michael G Chez; Natalie Guido-Estrada
Journal:  Neurotherapeutics       Date:  2010-07       Impact factor: 7.620

Review 5.  Beyond the brain: A multi-system inflammatory subtype of autism spectrum disorder.

Authors:  Robyn P Thom; Christopher J Keary; Michelle L Palumbo; Caitlin T Ravichandran; Jennifer E Mullett; Eric P Hazen; Ann M Neumeyer; Christopher J McDougle
Journal:  Psychopharmacology (Berl)       Date:  2019-05-28       Impact factor: 4.530

6.  Treatment of Autism Spectrum Disorder in Children and Adolescents.

Authors:  Melissa DeFilippis; Karen Dineen Wagner
Journal:  Psychopharmacol Bull       Date:  2016-08-15

Review 7.  Immune Abnormalities in Autism Spectrum Disorder-Could They Hold Promise for Causative Treatment?

Authors:  Dominika Gładysz; Amanda Krzywdzińska; Kamil K Hozyasz
Journal:  Mol Neurobiol       Date:  2018-01-06       Impact factor: 5.590

Review 8.  Impact of Immunoglobulin Therapy in Pediatric Disease: a Review of Immune Mechanisms.

Authors:  Priscilla H Wong; Kevin M White
Journal:  Clin Rev Allergy Immunol       Date:  2016-12       Impact factor: 8.667

9.  Immune Endophenotypes in Children With Autism Spectrum Disorder.

Authors:  Milo Careaga; Sally Rogers; Robin L Hansen; David G Amaral; Judy Van de Water; Paul Ashwood
Journal:  Biol Psychiatry       Date:  2015-09-11       Impact factor: 13.382

10.  Adaptive and Innate Immune Responses in Autism: Rationale for Therapeutic Use of Intravenous Immunoglobulin.

Authors:  Sudhir Gupta; Daljeet Samra; Sudhanshu Agrawal
Journal:  J Clin Immunol       Date:  2010-05       Impact factor: 8.317

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.